News DongKoo Bio & Pharma Co., Ltd.

Equities

A006620

KR7006620009

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
6,810 ^KRW	-1.87%		-1.30%	+20.32%

05-17	Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI
05-02	Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	05-16	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.	05-02	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.	05-02	CI
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on November 2, 2023, has expired with 321,701 shares, representing 1.17% for KRW 1,998.73 million.	05-01	CI
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor	04-11	CI
OTOM Co., Ltd. announced that it has received KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.	03-05	CI
HDT Co., Ltd announced that it expects to receive KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.	02-27	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.	02-02	CI
DongKoo Bio & Pharma Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.	11-02	CI
DongKoo Bio&Pharma Co., Ltd. authorizes a Buyback Plan.	11-01	CI
DongKoo Bio & Pharma Co., Ltd.(KOSDAQ:A006620) dropped from S&P Global BMI Index	18/09/23	CI
DongKoo Bio & Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23	CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.	09/08/22	CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.	08/08/22	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.	27/07/22	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.	27/07/22	CI
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on January 28, 2022, has expired with 416,327 shares, representing 1.49% for KRW 2,995.1 million.	26/07/22	CI
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.	28/04/22	CI
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on October 14, 2021.	13/04/22	CI
DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback announced on October 14, 2021, has expired with 251,612 shares, representing 0.89% for KRW 1,997.79 million.	12/04/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News DongKoo Bio & Pharma Co., Ltd.

Equities

A006620

KR7006620009

Summary

Filters